Cell Cycle Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
CASI | C | CASI Pharmaceuticals, Inc. | -0.41 | |
CYCCP | F | Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock | 2.74 | |
CYCC | F | Cyclacel Pharmaceuticals, Inc. | -3.41 |
Related Industries: Biotechnology
- Cell Cycle
Cell Cycle is a peer-reviewed scientific journal covering a range of cell biology related contents. It was founded in 2002 by its editor and editor-in-chief, Mikhail V. Blagosklonny (Roswell Park Cancer Institute), a distinguished physician-scientist. From publishing articles every two months, it now publishes bi-weekly, becoming one of the leading journals targeted towards cell biology.
The journal consists of well-knowledgeable persons within its Editorial Board, with 3 Nobel Prize winners and various scientists from the field. Over 7000 recognised articles/papers have been published on PubMed in 2015.
Various categories of manuscripts are published within the journal, ranging from research papers and reports, journal review articles and follow-ups of important Cell Cycle published articles.
The journal is abstracted and indexed in Medline/PubMed and the Science Citation Index Expanded. The journal is available through both hard copy and online formats for readers. It provides flexible access through its open policy, and offers online submission and peer-reviews of manuscripts by referees.
Some examples of published papers/articles can be found here:Cell cycle arrest is not yet senescence
Mitotic Arrest and Cell Fate
Popular Now
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Featured Articles